Search
Selected Filters
Displaying 1–10 of 394 news results
-
First patient treated with potential retinitis pigmentosa treatment from Sumitomo Pharma America
Research NewsCell therapy DSP-3077 is in Phase 1/2a clinical trials
-
Tarsus plans to purchase Alkeus, developer of emerging Stargardt treatment
Research NewsDeal marks another step as gildeuretinol advances towards patients
-
PRIMA retinal implant restores sight in patients with geographic atrophy from AMD
Research NewsProduct launched in Europe, U.S. approval in progress
-
FDA accepts new drug application, prioritizes review for potential Stargardt treatment
Research NewsBelite Bio’s tinlarebant could become the first-ever approved treatment for Stargardt disease
-
Summary of the 11th Annual Retinal Therapeutics Innovation Summit
Research NewsThe 11th annual Retinal Therapeutics Innovation Summit featured 25 presentations from industry professionals worldwide and more than 400 attendees.
-
Sepul Bio completes clinical trial enrollment for its USH2A retinitis pigmentosa treatment
Research NewsUltevursen from Sepul Bio progresses through phase 2b safety and efficacy clinical trial
-
FDA approves Lumvoa, a new treatment for thyroid eye disease
Research NewsApproval gives patients an additional option to manage TED symptoms
-
Belite Bio Submits New Drug Application to FDA for its Stargardt Treatment
Research NewsTinlarebant becomes first Stargardt treatment submitted to FDA for approval
-
Potential Oral Stargardt Treatment Advances to Phase 3 Clinical Trial
Research NewsPromising oral treatment moves closer for Stargardt patients.
-
Research News
2020 Llura Liggett Gund Award recipient honored for pioneering gene therapy that transformed vision research.
